158 related articles for article (PubMed ID: 38321270)
1. Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
Ahmadi P; Ghandili S; Jakobs F; Konnopka C; Morgner-Miehlke A; Kröger N; Ayuk F
Bone Marrow Transplant; 2024 Apr; 59(4):572-574. PubMed ID: 38321270
[No Abstract] [Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
5. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
Wang T; Gao L; Wang Y; Zhu W; Xu L; Wang Y; Yue W; Tang G; Chen L; Chen J; Zhang W; Yu X; Feng D; Yang J
Immunotherapy; 2020 Sep; 12(13):997-1006. PubMed ID: 32752910
[No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
Br J Haematol; 2022 Sep; 198(5):838-846. PubMed ID: 35765220
[TBL] [Abstract][Full Text] [Related]
8. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Lin RJ; Lobaugh SM; Pennisi M; Chan HT; Batlevi Y; Ruiz JD; Elko TA; Maloy MA; Batlevi CL; Dahi PB; Giralt SA; Hamlin PA; Mead E; Noy A; Palomba ML; Santomasso BD; Sauter CS; Scordo M; Shah GL; Korc-Grodzicki B; Kim SJ; Silverberg ML; Brooklyn CA; Devlin SM; Perales MA
Haematologica; 2021 Jan; 106(1):255-258. PubMed ID: 32079691
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
10. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
11. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
Jacobson CA; Farooq U; Ghobadi A
Oncologist; 2020 Jan; 25(1):e138-e146. PubMed ID: 31585984
[TBL] [Abstract][Full Text] [Related]
12. [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
Zhang Q; Xiao Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):788-792. PubMed ID: 36709176
[No Abstract] [Full Text] [Related]
13. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Hill BT; Roberts ZJ; Xue A; Rossi JM; Smith MR
Bone Marrow Transplant; 2020 Jun; 55(6):1184-1187. PubMed ID: 31471571
[No Abstract] [Full Text] [Related]
14. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Yamauchi N; Maruyama D
Eur J Haematol; 2024 May; 112(5):662-677. PubMed ID: 38168033
[TBL] [Abstract][Full Text] [Related]
15. CAR-T in B-Cell Lymphomas: The Past, Present, and Future.
Al-Juhaishi T; Ahmed S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e261-e268. PubMed ID: 34782260
[TBL] [Abstract][Full Text] [Related]
16. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
[No Abstract] [Full Text] [Related]
19. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
Bouziana S; Bouzianas D
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
Hunter BD; Chen YB; Jacobson CA
Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
